Quantcast

Latest Lymphocytic Leukemia Stories

2014-05-29 15:51:33

University of Chicago Medical Center Pinpointing cause of relapse could lead to better therapies A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of...

2014-05-28 23:16:46

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014 Tragara Pharmaceuticals, Inc. today announced the preliminary results of new preclinical research showing the activity of TG02, the company's unique oral cyclin dependent kinase (CDK) inhibitor, in chronic lymphocytic leukemia (CLL). Researchers at The Ohio State University demonstrated that TG02 is highly active in CLL cells derived...

2014-05-14 23:05:42

RnRMarketResearch.com adds “EpiCast Report Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023” to its store. Develop business strategies by understanding the trends shaping and driving the global ALS & CLL market. Dallas, Texas (PRWEB) May 14, 2014 EpiCast Report: Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2023 Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig’s Disease,” is a rare, but...

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias...

2014-05-02 08:24:57

First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Financial Results for the Quarter Ended March 31, 2014 GAAP and Non-GAAP net income (loss) Non-GAAP net income reported for the quarter ended March 31, 2014 was $31.3 million, or $0.40 net income per diluted share,...

2014-04-25 23:01:04

The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography; http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html. (PRWEB) April 26, 2014 The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers, restraints, and opportunities in...

2014-04-23 16:30:09

DUBLIN, April 23, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3mgfnj/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" [http://www.researchandmarkets.com/research/3mgfnj/acute ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The acute...

2014-04-22 08:32:53

FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra(®) was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra(®). In the clinical trials results were evaluated based on...

2014-04-21 13:46:28

Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven't been able to explain why. Now, a team of Dana-Farber Cancer Institute investigators has uncovered a connection between the two conditions. In a study posted online today by the journal Nature Genetics, the researchers track the genetic chain of events that links a chromosomal abnormality in Down syndrome to the cellular havoc...

2014-04-21 12:27:29

SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE(TM)) study of single agent IMBRUVICA(TM) (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of IMBRUVICA after three years of follow-up, will be presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, Illinois May 30 - June...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.